SIGNUM BIOSCIENCES, INC.

Company Information
Address 11 DEERPARK DR STE 202
MONMOUTH JUNCTION, NJ, 08852-1923


Information

DUNS: 144196354

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A Topical Non-steroidal Anti-inflammatory for Atopic Dermatitis

    Amount: $1,050,155.00

    SUMMARY Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young children Current treatments are associated with a wide range of side effects therefore development ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. A Topical Non-steroidal Anti-inflammatory for Atopic Dermatitis

    Amount: $1,675,030.00

    DESCRIPTION (provided by applicant): Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young children. Current treatments are associated with a wide range of side e ...

    SBIRPhase II2013Department of Health and Human Services
  3. A Topical Non Steroidal Anti-inflammatory for Rosacea

    Amount: $2,975,892.00

    DESCRIPTION (provided by applicant): Rosacea is a chronic dermatological condition characterized by flushing, erythema, papules, pustules, inflammatory nodules and telangiectasia. Although disease eti ...

    SBIRPhase II2011Department of Health and Human Services
  4. A Novel Class of Therapeutic Agents for the Treatment of Skin Diseases Associated

    Amount: $356,919.00

    DESCRIPTION (provided by applicant): N-acetyl-S-famesyl-L-cysteine (AFC) and its derivatives (isoprenylcysteine (IPC) analogs) represent a novel class of topically absorbed NSAIDs whose activity is re ...

    SBIRPhase I2010Department of Health and Human Services
  5. A Novel Class of Topical Pleitropic Anti-Acne Therapeutics

    Amount: $327,178.00

    DESCRIPTION (provided by applicant): Acne is a multifactorial disease affecting ~50 million people in the US. Three main factors contribute to the pathogenesis of acne; 1) P. acnes growth 2) P. ac ...

    SBIRPhase I2010Department of Health and Human Services
  6. Phosphoprotein phosphatase 2A, a new target for Alzheimer's Disease interventio

    Amount: $324,717.00

    DESCRIPTION (provided by applicant): Abnormal hyperphosphorylation of tau plays an important role in Alzheimer's disease (AD) and other tauopathies. Current therapeutic approaches with focus on tau ki ...

    SBIRPhase I2010Department of Health and Human Services
  7. Topical Non-Steroidal Anti-Inflammatories for the Treatment of Rosacea

    Amount: $1,568,460.00

    DESCRIPTION (provided by applicant): Isoprenylcysteine (IPC) analogs modulate heterotrimeric G-protein coupled receptor (GPCR) signaling pathways, representing a novel class of topical anti-inflammato ...

    SBIRPhase II2009Department of Health and Human Services
  8. A Novel Class of Non Steroidal Anti-Inflammatories

    Amount: $298,744.00

    DESCRIPTION (provided by applicant): Isoprenylcysteine (IPC) analogs, such as N-acetyl-S-farnesyl-L-cysteine (AFC) modulate heterotrimeric G- protein and Ras-related signaling pathways, representing ...

    SBIRPhase I2008Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government